Dizal Pharmaceuticals

Biomarkers

• EGFR exon 19 deletion / L858R3
• EGFR exon 20 insertion3
• HER2 (ERBB2) activating mutation1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

sunvozertinib 6DZD6008 4osimertinib 1bevacizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2027-06 DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) Phase 1/2 · EGFR exon 19 deletion / L858R

Trials

8 of 12 trials shown

1. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

   Active, not recruiting Phase 3 Dizal Pharmaceuticals Started 2022Primary completion 2026-01 NCT05668988

   sunvozertinib FDApemetrexedcarboplatin

   Adequate tumor tissue available, for central laboratory confirmation of EGFR exon 20 insertion mutation

   EGFR exon 20 insertionNon-small Cell Lung Cancer

2. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

   Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025Primary completion 2028-06 NCT07079475

   DZD6008sunvozertinibosimertinib FDA EU

   Part B: EGFR sensitizing mutations (Exon19del and/or L858R) with or without T790M/C797S resistance mutations.

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

3. DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

   Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025Primary completion 2027-06 NCT07070440

   DZD6008pemetrexedcarboplatindocetaxel

   Documentation of EGFR sensitizing mutation confirmed by local laboratory.

   EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

4. DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

   Recruiting Phase 2 Dizal Pharmaceuticals Started 2023Primary completion 2025-12 NCT06276283

   sunvozertinib FDAbevacizumab

   …A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.

   EGFR exon 20 insertionNon-small Cell Lung Cancer

5. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

   Active, not recruiting Phase 2 Dizal Pharmaceuticals Started 2021Primary completion 2022-10 NCT05712902

   sunvozertinib FDA

   Tumor tissue EGFR exon 20 insertion mutations confirmed by qualified local laboratories or sponsor-designated central laborat…

   EGFR exon 20 insertionNon-Small Cell Lung Cancer

6. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

   Active, not recruiting Phase 1/2 Dizal Pharmaceuticals Started 2019Primary completion 2024-07 NCT03974022

   sunvozertinib

   …ocumented histological or cytological confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations.

   EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationNon-Small Cell Lung Cancer

7. A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

   Recruiting Phase 1 Dizal Pharmaceuticals Started 2025Primary completion 2027-09 NCT06905197

   DZD6008sunvozertinib

   For Part A monotherapy cohorts and all cohorts of Part B, EGFR sensitizing mutations (Exon19del and/or L858R) are required.

   EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

8. Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

   Recruiting Phase 1 Dizal Pharmaceuticals Started 2024Primary completion 2027-10 NCT06813365

   DZD6008

   Documentation of EGFR sensitizing mutation (Exon19del and/or L858R) from a local CLIA-certified laboratory (or equivalent).

   EGFR exon 19 deletion / L858RNonsmall-cell Lung Cancer

No trials match these filters.